J. Goudemand

发表

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

J. Goudemand, S. Lethagen, J. Eikenboom, 2008, Journal of thrombosis and haemostasis : JTH.

Fifth Åland Island conference on von Willebrand disease

M. Blombäck, P. T. Onundarson, P. Mannucci, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

A. Tosetto, J. Batlle, F. Rodeghiero, 2010, Thrombosis research.

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels

D. Hampshire, A. Federici, P. Winship, 2010, Journal of thrombosis and haemostasis : JTH.

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

J. Goudemand, S. Lethagen, J. Eikenboom, 2009, Journal of Thrombosis and Haemostasis.

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

J. Goudemand, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

P. Mannucci, C. Rothschild, A. Borel‐Derlon, 2007, Journal of thrombosis and haemostasis : JTH.

Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity

J. Goudemand, C. Mazurier, C. Caron, 1992, British journal of haematology.

Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

C. Rothschild, M. Bertrand, J. Goudemand, 1997, Thrombosis and Haemostasis.

Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2007, Journal of thrombosis and haemostasis : JTH.

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice

G. Spotts, J. Oldenburg, L. Valentino, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Experiences with continuous infusion of recombinant activated factor VII.

M. Morfini, J. Goudemand, C. Négrier, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Response to Wiewel‐Verschueren S et al.: gynaecological and obstetrical bleeding in women with factor XI deficiency – a systematic review

E. de Raucourt, J. Goudemand, F. Bauduer, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.